의료용 플라스틱 시장 : 유형별, 용도별, 지역별 - 세계 예측(-2031년)

The global medical plastics market is expected to be valued at USD 34.77 billion in 2026 and USD 48.77 billion by 2031, registering a CAGR of 7.0% during the forecast period. Rising demand for advanced medical devices and single-use healthcare products is driving the market. The mounting demand for safe, lightweight, and efficient polymers for healthcare applications and the growing incidence of chronic diseases among an aging population create market growth opportunities.

Furthermore, the increasing use of minimally invasive procedures, combined with the use of disposable medical devices to decrease infection rates, also adds to the momentum of the market.

"High-performance plastics segment to record the highest CAGR from 2026 to 2031"

In terms of type, the high-performance plastics segment is anticipated to be the fastest-growing in the medical plastics market during the forecast period. The segmental growth is attributed to its remarkable mechanical strength, chemical resistance, excellent thermal stability, and biocompatibility. High-tech materials, including PEEK, PTFE, and PPSU, represent this segment. It is embraced in high-end medical applications looking for high reliability and performance under demanding medical conditions. Orthopedic and spinal implants, surgical instruments, catheter parts, drug delivery systems, dental devices, and tools used in repeated sterilization are among the key applications of these materials due to their low weight, dimensional stability, resistance to wear, and repeated sterilization ability. In addition, they can replace metals in the field while being radiolucent and offering corrosion resistance and design flexibility.

"Medical disposables segment to hold the largest share of the medical plastics market in 2031"

In terms of application, the medical disposables segment is projected to capture the largest market share in 2031, owing to the extensive usage in hospitals, ambulatory care facilities, diagnostic laboratories, and home healthcare. Various products, including syringes, gloves, IV components, blood collection devices, surgical disposables, specimen containers, and disposable respiratory products, heavily depend on medical-grade plastics to maintain sterility and ensure patient safety at a cost-effective production level. Increasing volumes of surgical procedures, rising measures taken for infection prevention, growing vaccination and diagnostic programs, and increasing popularity of disposable plastic products drive the demand for medical disposables. Moreover, the stringent regulatory framework and the emphasis on the prevention of hospital-acquired infections solidify the market leadership of the segment.

"Europe to be the second-largest region in the medical plastics market during the forecast period"

In terms of region, Europe is anticipated to hold the second-largest share of the medical plastic market between 2026 and 2031 due to the advanced medical device manufacturing industry, better healthcare infrastructure, and strict regulations governing medical plastic and patient safety. The region houses many prominent manufacturers of medical devices, polymers, and other packaging products for healthcare, hence stimulating innovations in high-performance medical plastics. Increased need for minimally invasive procedures, aging populations, growing prevalence of chronic diseases, and expansion of the pharmaceutical and biotech industry are driving the regional market.

Breakdown of Primary Interviews:

By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%

By Designation: Directors: 30%, Managers: 20%, and Others: 50%

By Region: North America: 20%, Europe: 10%, Asia Pacific: 40%, South America: 10%, and Middle East & Africa: 20%

Notes: Others include sales, marketing, and product managers.

Tier 1: >USD 1 Billion; Tier 2: USD 500 million-1 Billion; and Tier 3: <USD 500 million

Companies Covered: BASF (Germany), Celanese Corporation (US), SABIC (Saudi Arabia), Covestro AG (Germany), Syensqo (Belgium), Evonik Industries (Germany), Arkema (France), Lubrizol (US), Ensinger (Germany), and Dow (US), among others, are covered in the report.

The study includes an in-depth competitive analysis of these key players in the medical plastics market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the medical plastics market based on type (standard plastics, engineering plastics, high-performance plastics, silicone, and other types) and application (medical disposables, medical instruments & devices, prosthetics & implants, drug delivery, medical packaging, and other applications). The report's scope covers detailed information regarding drivers, restraints, challenges, and opportunities influencing the market growth. A detailed analysis of the key industry players has been done to provide insights into their business overviews, products offered, and key strategies, such as mergers, acquisitions, product launches, and expansions, associated with the medical plastics market. This report covers a competitive analysis of upcoming startups in the medical plastics market ecosystem.

Reasons to Buy the Report

The report will offer the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall medical plastics market and the subsegments. This report will help stakeholders understand the competitive landscape, gain more insights into positioning their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following points:

• Analysis of key drivers (Rising demand for single-use and disposable medical devices, Growing global aging population and chronic disease burden, Increasing adoption of advanced medical devices and minimally invasive procedures), restraints (Stringent regulatory and material validation requirements, Environmental concerns related to plastic waste), opportunities (Growing adoption of bio-based and sustainable medical plastics, Expanding healthcare infrastructure in emerging economies), and challenges (Issues in balancing sustainability requirements with stringent medical performance standards, Supply chain complexity for high-performance medical-grade polymers)
• Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and product & service launches in the medical plastics market
• Market Development: Comprehensive information about profitable markets (the report analyzes the medical plastics market across varied regions)
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the medical plastics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as BASF (Germany), Celanese Corporation (US), SABIC (Saudi Arabia), Covestro AG (Germany), Syensqo (Belgium), Evonik Industries (Germany), Arkema (France), Lubrizol (US), Ensinger (Germany), and Dow (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
  • 1.3.5 UNITS CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MEDICAL PLASTICS MARKET
• 3.2 ASIA PACIFIC: MEDICAL PLASTICS MARKET, BY APPLICATION AND COUNTRY
• 3.3 MEDICAL PLASTICS MARKET, BY TYPE
• 3.4 MEDICAL PLASTICS MARKET, BY COUNTRY

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising demand for single-use and disposable medical devices
    • 4.2.1.2 Growing global aging population and rising chronic disease burden
    • 4.2.1.3 Increasing adoption of advanced medical devices and minimally invasive procedures
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Stringent regulatory and material validation requirements
    • 4.2.2.2 Environmental concerns related to plastic waste
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing adoption of bio-based and sustainable medical plastics
    • 4.2.3.2 Expanding healthcare infrastructure in emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Balancing sustainability requirements with stringent medical performance standards
    • 4.2.4.2 Supply chain complexity for high-performance medical-grade polymers
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN MEDICAL PLASTICS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • 4.5.1 KEY MOVES AND STRATEGIC FOCUS
• 4.6 PORTER'S FIVE FORCES ANALYSIS
  • 4.6.1 BARGAINING POWER OF SUPPLIERS
  • 4.6.2 BARGAINING POWER OF BUYERS
  • 4.6.3 THREAT OF SUBSTITUTES
  • 4.6.4 THREAT OF NEW ENTRANTS
  • 4.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.7 VALUE CHAIN ANALYSIS
  • 4.7.1 RAW MATERIAL SUPPLIERS
  • 4.7.2 DISTRIBUTORS
  • 4.7.3 MANUFACTURERS
  • 4.7.4 END CONSUMERS
• 4.8 ECOSYSTEM
• 4.9 PRICING ANALYSIS
  • 4.9.1 AVERAGE SELLING PRICE TREND, BY REGION
• 4.10 MACROECONOMIC INDICATORS
  • 4.10.1 GLOBAL GDP TRENDS
  • 4.10.2 HEALTHCARE INDUSTRY TRENDS
• 4.11 IMPACT OF 2025 US TARIFFS ON MEDICAL PLASTICS MARKET
  • 4.11.1 INTRODUCTION
  • 4.11.2 KEY TARIFF RATES
  • 4.11.3 PRICE IMPACT ANALYSIS
  • 4.11.4 IMPACT ON COUNTRIES/REGIONS
    • 4.11.4.1 US
    • 4.11.4.2 Europe
    • 4.11.4.3 Asia Pacific
  • 4.11.5 IMPACT ON END-USE INDUSTRIES
• 4.12 TRADE ANALYSIS
  • 4.12.1 IMPORT SCENARIO (HS CODE 3926)
  • 4.12.2 EXPORT SCENARIO (HS CODE 3926)
• 4.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 4.14 INVESTMENT AND FUNDING SCENARIO
• 4.15 CASE STUDY ANALYSIS
  • 4.15.1 COVESTRO AG INTRODUCES CIRCULAR MEDICAL-GRADE POLYCARBONATE FOR HEALTHCARE APPLICATIONS
  • 4.15.2 CELANESE CORPORATION EXPANDS GUR UHMW-PE PORTFOLIO FOR MEDICAL APPLICATIONS
  • 4.15.3 EVONIK INDUSTRIES ADVANCES IMPLANTABLE BIOMATERIALS FOR MEDICAL DEVICES
• 4.16 KEY CONFERENCES & EVENTS

5 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 5.1 TECHNOLOGY ANALYSIS
  • 5.1.1 KEY TECHNOLOGIES
    • 5.1.1.1 Bio-based and bio-attributed medical-grade polymers
    • 5.1.1.2 High-performance polymers for implantable and minimally invasive devices
    • 5.1.1.3 Medical-grade additive manufacturing (3D printing) of polymers
  • 5.1.2 COMPLEMENTARY TECHNOLOGIES
    • 5.1.2.1 AI-powered quality inspection and smart manufacturing systems
    • 5.1.2.2 Digital twin technology for manufacturing process optimization
• 5.2 TECHNOLOGY/PRODUCT ROADMAP
  • 5.2.1 SHORT TERM (2025-2027) | MATERIAL INNOVATION & REGULATORY FOUNDATION
  • 5.2.2 MID-TERM (2027-2030) | SMART MATERIALS & DIGITAL MANUFACTURING
  • 5.2.3 LONG TERM (2030-2030+) | SUSTAINABLE HIGH-PERFORMANCE MATERIALS & AUTONOMOUS MANUFACTURING
• 5.3 PATENT ANALYSIS
  • 5.3.1 LEGAL STATUS OF PATENTS
  • 5.3.2 JURISDICTION ANALYSIS
• 5.4 FUTURE APPLICATIONS
  • 5.4.1 ADVANCED SINGLE-USE MEDICAL DEVICES & INFECTION PREVENTION
  • 5.4.2 ADVANCED DRUG DELIVERY & COMBINATION MEDICAL DEVICES
  • 5.4.3 BIOPHARMACEUTICAL MANUFACTURING & ADVANCED THERAPIES
  • 5.4.4 SMART DIAGNOSTICS, WEARABLE HEALTHCARE & HOME MEDICAL DEVICES
  • 5.4.5 ROBOTIC SURGERY, MINIMALLY INVASIVE DEVICES & HIGH-PERFORMANCE MEDICAL COMPONENTS
• 5.5 IMPACT OF AI/GEN AI ON MEDICAL PLASTICS MARKET
  • 5.5.1 TOP USE CASES AND MARKET POTENTIAL OF MEDICAL PLASTICS
  • 5.5.2 BEST PRACTICES IN MEDICAL PLASTICS PROCESSING
  • 5.5.3 CASE STUDIES OF AI IMPLEMENTATION IN MEDICAL PLASTICS MARKET
  • 5.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 5.5.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN MEDICAL PLASTICS MARKET

6 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 6.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 6.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.1.2 INDUSTRY STANDARDS
• 6.2 IMPACT OF REGULATORY POLICIES AND SUSTAINABILITY INITIATIVES
• 6.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 7.1 INTRODUCTION
• 7.2 DECISION-MAKING PROCESS
• 7.3 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 7.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 7.3.2 BUYING CRITERIA
• 7.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 7.5 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
• 7.6 MARKET PROFITABILITY
  • 7.6.1 REVENUE POTENTIAL
  • 7.6.2 COST DYNAMICS
  • 7.6.3 MARGIN OPPORTUNITIES IN KEY END-USE INDUSTRIES

8 MEDICAL PLASTICS MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 POLYPROPYLENE (PP)
  • 8.2.1 HIGH FATIGUE RESISTANCE AND STERILIZATION STABILITY SUPPORTING REUSABLE AND DISPOSABLE DEVICES
• 8.3 POLYVINYL CHLORIDE (PVC)
  • 8.3.1 EXCELLENT FLEXIBILITY, STERILIZATION COMPATIBILITY, AND COST EFFICIENCY TO SUPPORT HIGH-VOLUME MEDICAL APPLICATIONS
• 8.4 POLYETHYLENE (PE)
  • 8.4.1 OUTSTANDING CHEMICAL RESISTANCE AND BIOCOMPATIBILITY DRIVING DISPOSABLE HEALTHCARE PRODUCTS
• 8.5 POLYSTYRENE (PS)
  • 8.5.1 SUPERIOR CLARITY AND DIMENSIONAL PRECISION ENABLING DIAGNOSTIC AND LABORATORY APPLICATIONS
• 8.6 POLYMETHYL METHACRYLATE (PMMA)
  • 8.6.1 HIGH OPTICAL TRANSPARENCY AND WEATHER RESISTANCE ADVANCING SPECIALIZED MEDICAL DEVICES
• 8.7 ENGINEERING AND HIGH PERFORMANCE PLASTICS
  • 8.7.1 POLYETHER ETHER KETONE (PEEK)
    • 8.7.1.1 Superior mechanical performance and biocompatibility accelerating implant innovation
  • 8.7.2 POLYAMIDE (PA)
    • 8.7.2.1 Excellent mechanical strength and wear resistance supporting precision medical components
  • 8.7.3 POLYPHENYLSULFONE (PPSU)
    • 8.7.3.1 Excellent sterilization durability and impact resistance supporting reusable medical devices
  • 8.7.4 POLYSULFONE (PSU)
    • 8.7.4.1 High thermal stability and hydrolytic resistance driving adoption in reusable medical devices
  • 8.7.5 POLYCARBONATE (PC)
    • 8.7.5.1 Exceptional transparency and impact resistance supporting advanced healthcare devices
  • 8.7.6 ACRYLONITRILE BUTADIENE STYRENE (ABS)
    • 8.7.6.1 High impact strength and dimensional stability enabling durable medical equipment
  • 8.7.7 OTHER ENGINEERING AND HIGH-PERFORMANCE PLASTICS
• 8.8 OTHER TYPES

9 MEDICAL PLASTICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 MEDICAL DISPOSABLES
  • 9.2.1 MEDICAL BAGS
    • 9.2.1.1 Reliable fluid containment and sterility driving demand in healthcare
  • 9.2.2 CATHETERS
    • 9.2.2.1 Precision polymer technologies enabling minimally invasive therapies
  • 9.2.3 SYRINGES
    • 9.2.3.1 High-volume disposable devices supporting safe drug administration
  • 9.2.4 OTHER DISPOSABLES
• 9.3 MEDICAL INSTRUMENTS & DEVICES
  • 9.3.1 SURGICAL INSTRUMENTS
    • 9.3.1.1 Lightweight engineering polymers improving surgical precision
  • 9.3.2 DIAGNOSTIC DEVICES
    • 9.3.2.1 Precision plastics enabling accurate diagnostic performance
  • 9.3.3 DENTAL INSTRUMENTS
    • 9.3.3.1 Durable biocompatible polymers advancing dental treatments
• 9.4 PROSTHETICS & IMPLANTS
  • 9.4.1 LIMB PROSTHETICS
    • 9.4.1.1 Lightweight high-strength polymers enhancing patient mobility
  • 9.4.2 IMPLANTS
    • 9.4.2.1 Advanced biomaterials improving long-term clinical performance
• 9.5 DRUG DELIVERY
• 9.6 MEDICAL PACKAGING
• 9.7 OTHER APPLICATIONS

10 MEDICAL PLASTICS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 US
    • 10.2.1.1 FDA regulatory excellence, robust healthcare spending, and advanced medical device manufacturing to drive market
  • 10.2.2 CANADA
    • 10.2.2.1 Universal healthcare investments, regulatory modernization, and expanding home healthcare services to accelerate growth
  • 10.2.3 MEXICO
    • 10.2.3.1 Nearshoring investments, export-oriented medical device manufacturing, and regulatory reforms propelling demand
• 10.3 EUROPE
  • 10.3.1 GERMANY
    • 10.3.1.1 Advanced medical device manufacturing, healthcare reforms, and aging population to fuel demand
  • 10.3.2 FRANCE
    • 10.3.2.1 Biopharmaceutical innovation, government healthcare investments, and France 2030 Strategy to strengthen market
  • 10.3.3 SPAIN
    • 10.3.3.1 Strong economic growth, healthcare digitalization, and medical device investments accelerating market growth
  • 10.3.4 UK
    • 10.3.4.1 NHS investment, regulatory modernization, and life sciences innovation driving growth
  • 10.3.5 ITALY
    • 10.3.5.1 Mirandola biomedical cluster, healthcare modernization, and medical device manufacturing strength supporting market
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 CHINA
    • 10.4.1.1 Manufacturing scale, regulatory modernization, and healthcare investments driving market
  • 10.4.2 JAPAN
    • 10.4.2.1 Aging demographics, rising healthcare expenditure, and stringent regulatory standards to support market growth
  • 10.4.3 INDIA
    • 10.4.3.1 Production-linked incentives, healthcare infrastructure expansion, and rising domestic manufacturing to propel market
  • 10.4.4 SOUTH KOREA
    • 10.4.4.1 Government MedTech investments, advanced manufacturing, and digital healthcare expansion driving market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 MIDDLE EAST & AFRICA
  • 10.5.1 GCC COUNTRIES
    • 10.5.1.1 Healthcare infrastructure expansion, rising chronic disease burden, and medical technology investments to fuel demand
    • 10.5.1.2 Saudi Arabia
      • 10.5.1.2.1 Vision 2030 healthcare transformation, medical infrastructure investments, and regulatory modernization to support market growth
    • 10.5.1.3 UAE
      • 10.5.1.3.1 Healthcare hub development, regulatory transformation, and medical tourism drive market
    • 10.5.1.4 Rest of GCC
  • 10.5.2 SOUTH AFRICA
    • 10.5.2.1 National health insurance reform, expanding healthcare access, and rising chronic disease burden to support market
  • 10.5.3 REST OF MIDDLE EAST & AFRICA
• 10.6 SOUTH AMERICA
  • 10.6.1 BRAZIL
    • 10.6.1.1 Universal healthcare expansion, healthcare infrastructure investments, and regulatory modernization to drive market
  • 10.6.2 ARGENTINA
    • 10.6.2.1 Macroeconomic stabilization, regulatory modernization, and rising healthcare demand to accelerate market
  • 10.6.3 REST OF SOUTH AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYERS' STRATEGIES/RIGHT TO WIN
• 11.3 REVENUE ANALYSIS, 2021-2025
• 11.4 MARKET SHARE ANALYSIS, 2025
• 11.5 PRODUCT COMPARISON
• 11.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 11.6.1 STARS
  • 11.6.2 EMERGING LEADERS
  • 11.6.3 PERVASIVE PLAYERS
  • 11.6.4 PARTICIPANTS
  • 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 11.6.5.1 Company footprint
    • 11.6.5.2 Region footprint
    • 11.6.5.3 Type footprint
    • 11.6.5.4 Application footprint
• 11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 11.7.1 PROGRESSIVE COMPANIES
  • 11.7.2 RESPONSIVE COMPANIES
  • 11.7.3 DYNAMIC COMPANIES
  • 11.7.4 STARTING BLOCKS
  • 11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 11.7.5.1 Detailed list of key startups/SMEs
    • 11.7.5.2 Competitive benchmarking of key startups/SMEs
• 11.8 COMPANY VALUATION & FINANCIAL METRICS
  • 11.8.1 FINANCIAL METRICS
  • 11.8.2 COMPANY VALUATION
  • 11.8.3 ENTERPRISE VALUATION
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 BASF
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Solutions/Services offered
      • 12.1.1.2.1 Recent developments
      • 12.1.1.2.2 Expansions
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Right to win
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses and competitive threats
  • 12.1.2 CELANESE CORPORATION
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Solutions/Services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 SABIC
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Solutions/Services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 COVESTRO AG
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Solutions/Services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 SYENSQO
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Solutions/Services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 EVONIK INDUSTRIES
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Solutions/Services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches
      • 12.1.6.3.2 Expansions
    • 12.1.6.4 MnM view
  • 12.1.7 ARKEMA
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Solutions/Services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches
      • 12.1.7.3.2 Deals
    • 12.1.7.4 MnM view
  • 12.1.8 LUBRIZOL
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Solutions/Services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
      • 12.1.8.3.2 Deals
      • 12.1.8.3.3 Expansions
    • 12.1.8.4 MnM view
  • 12.1.9 ENSINGER
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Solutions/Services offered
    • 12.1.9.3 MnM view
  • 12.1.10 DOW
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Solutions/Services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
    • 12.1.10.4 MnM view
• 12.2 OTHER PLAYERS
  • 12.2.1 TRINSEO
  • 12.2.2 BIOMERICS
  • 12.2.3 ENVALIOR
  • 12.2.4 EASTMAN CHEMICAL COMPANY
  • 12.2.5 INVIBIO LTD.
  • 12.2.6 LYONDELLBASELL INDUSTRIES HOLDINGS B.V.
  • 12.2.7 MITSUBISHI CHEMICAL GROUP
  • 12.2.8 AVIENT CORPORATION
  • 12.2.9 ROCHLING SE & CO. KG
  • 12.2.10 RTP COMPANY
  • 12.2.11 SAINT-GOBAIN
  • 12.2.12 TEKNI-PLEX, INC.
  • 12.2.13 TEKNOR APEX COMPANY
  • 12.2.14 WACKER CHEMIE AG
  • 12.2.15 GEON PERFORMANCE SOLUTIONS LLC

13 RESEARCH METHODOLOGY

• 13.1 RESEARCH DATA
  • 13.1.1 SECONDARY DATA
    • 13.1.1.1 Key data from secondary sources
  • 13.1.2 PRIMARY DATA
    • 13.1.2.1 Key data from primary sources
    • 13.1.2.2 Key industry insights
• 13.2 MARKET SIZE ESTIMATION
• 13.3 BASE NUMBER CALCULATION
• 13.4 MARKET FORECAST APPROACH
• 13.5 DATA TRIANGULATION
• 13.6 FACTOR ANALYSIS
• 13.7 RESEARCH ASSUMPTIONS
• 13.8 RESEARCH LIMITATIONS AND RISK ASSESSMENT

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS